Kevetrin thioureidobutyronitrile: Phase I started

Cellceutix began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV Kevetrin given once weekly for the first 3 weeks of a 4-week cycle in about 40 patients with advanced solid tumors. I...